Home › Funds › Ikarian Capital, LLC › DRUG

Ikarian Capital, LLC position in DRUG

BRIGHT MINDS BIOSCIENCES INC · Health Care

Ikarian Capital, LLC reported holding 88,951 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.65% of its reported portfolio and ranking #41 among its reported holdings. Ikarian Capital, LLC has disclosed DRUG holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)88.95K sh
Reported value held$4.43M
Portfolio Weight0.65%
First reportedQ4 2024
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's DRUG position evolved

Ikarian Capital, LLC first disclosed a stake in DRUG in Q4 2024 at 152,211 shares (US$5.5M). The position peaked in Q4 2025 at 159,421 shares, worth US$12.4M. Across 8 filings, Ikarian Capital, LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 88,951 shares valued at US$4.4M. Notable position changes include a 57% trim in Q1 2025 (shares fell 28% over the following quarter), a 76% trim in Q3 2025 (shares rose 29% over the following quarter), a 933% increase in Q4 2025 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 152.21K $5.48M New
Q1 2025 65.43K $2.36M Reduce
Q2 2025 65.43K $1.71M Hold
Q3 2025 15.43K $936.04K Reduce
Q4 2025 159.42K $12.44M Add
Q1 2026 166.65K $12.16M Add
Q2 2026 88.95K $6.24M Reduce
Q3 2026 88.95K $4.43M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DRUG and 13F data

DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 60 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$39.9M), Vestal Point Capital, LP (US$27.2M), BRAIDWELL LP (US$24.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DRUG

All DRUG fund holders →

FAQ

How long has Ikarian Capital, LLC held DRUG?

Ikarian Capital, LLC has disclosed DRUG holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Ikarian Capital, LLC's current position in DRUG?

As of Q3 2026, Ikarian Capital, LLC holds 88.95K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $4.43M, representing 0.65% of its reported portfolio and ranking #41.

Has Ikarian Capital, LLC been buying or selling DRUG?

In the latest 13F filing (Q3 2026), Ikarian Capital, LLC held unchanged its position in DRUG. The position peaked in Q4 2025 at 159.42K shares.

Which other funds hold DRUG?

Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vestal Point Capital, LP, BRAIDWELL LP, among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.